Literature DB >> 21178410

Prolonged infection by Fonsecaea pedrosoi after antigenic co-stimulation at different sites in experimental murine chromoblastomycosis.

Alexandre Paulo Machado1, Maria Regina Regis Silva, Olga Fischman.   

Abstract

In the present study, we examined prolonged infection after antigenic co-stimulation by inoculation of the fungus Fonsecaea pedrosoi at two different sites in three mouse strains (BALB/c, Swiss, and C57BL/6). Using this murine model of infection, we showed that antigen induction of infection at more than one site led to a local suppression of active lesions, which increased the time course of experimental chromoblastomycosis (CBM). Footpad infection with a simultaneous infection of the peritoneum or a mucosal site appeared to cause prolonged infection and frequent fungal disseminations. Using knockout (KO) mice, we observed that antigenic co-stimulation caused progressive illness in CD8-KO animals and an effective immune response in the absence of IL-10. In Xid mice, co-stimulation provoked chronic infection (not prolonged), suggesting that B1 B cells play an important role in the control of fungal infection. The tissue response to infection was similar in all co-stimulated mouse groups, as anatomopathologic sections revealed multifocal lesions (granuloma-like). In general, these mice had acute responses at primary antigenic sites with an intense migration of polymorphonuclear leukocytes (PMNs), whereas the distant infection sites (footpad) showed signs of chronic infection. The migration of PMNs to the secondary site (footpad) increased in the later periods of infection, especially after the disappearance of the primary antigenic focus. PMN migration was associated with lesion-dormancy breakage and fungal elimination. Our findings suggest that the host inflammatory/suppression mechanisms induced by antigenic co-stimulation to systemically fight the same pathogen act coordinately through responses that differ at the sites of infection between acute and chronic integrated healing processes that are more prolonged than an acute infection at a single site. However, the long persistence of fungal cells in the host may be linked to microbial adaptation to a parasitic infection as observed in co-stimulated Xid mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178410      PMCID: PMC3080202          DOI: 10.4161/viru.1.1.9920

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  38 in total

1.  Development of a chronic chromoblastomycosis model in immunocompetent mice.

Authors:  N Cardona-Castro; P Agudelo-Flórez
Journal:  Med Mycol       Date:  1999-04       Impact factor: 4.076

Review 2.  Suppression of the immune response by microorganisms.

Authors:  J H Schwab
Journal:  Bacteriol Rev       Date:  1975-06

3.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

Authors:  Yasmine Belkaid; Ciriaco A Piccirillo; Susana Mendez; Ethan M Shevach; David L Sacks
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

Review 4.  Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance.

Authors:  Ciriaco A Piccirillo; Ethan M Shevach
Journal:  Semin Immunol       Date:  2004-04       Impact factor: 11.130

Review 5.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

6.  Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response.

Authors:  P J Cooper; I Espinel; M Wieseman; W Paredes; M Espinel; R H Guderian; T B Nutman
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis.

Authors:  Daniel Elias; Hannah Akuffo; Andrzej Pawlowski; Melles Haile; Thomas Schön; Sven Britton
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

8.  Onchocerciasis modulates the immune response to mycobacterial antigens.

Authors:  G R Stewart; M Boussinesq; T Coulson; L Elson; T Nutman; J E Bradley
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

Review 9.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity.

Authors:  Susana Mendez; Stacie K Reckling; Ciriacco A Piccirillo; David Sacks; Yasmine Belkaid
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  4 in total

1.  Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved.

Authors:  Claudio Guedes Salgado
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

2.  Study of tissue inflammatory response in different mice strains infected by dematiaceous fungi Fonsecaea pedrosoi.

Authors:  Marilia Marufuji Ogawa; Mario Mariano; Maria Regina Regis Silva; Milvia Maria Simões E Silva Enokihara; Nilceo Schwery Michalany; Angela Satie Nishikaku; Agenor Messias Silvestre; Jane Tomimori
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

Review 3.  Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis.

Authors:  Leandro C D Breda; Isabela G Menezes; Larissa N M Paulo; Sandro Rogério de Almeida
Journal:  J Fungi (Basel)       Date:  2020-12-22

Review 4.  Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.

Authors:  Luiz Felipe Domingues Passero; Italo Novais Cavallone; Walter Belda
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.